Predicting residual disease in cancer ovary with tumour markers
Not Applicable
- Conditions
- Health Condition 1: C562- Malignant neoplasm of left ovaryHealth Condition 2: C561- Malignant neoplasm of right ovaryHealth Condition 3: C569- Malignant neoplasm of unspecifiedovary
- Registration Number
- CTRI/2020/12/029922
- Lead Sponsor
- Dr Rajlaxmi Mundhra
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients of epithelial ovarian malignancy planned for primary or interval debulking surgery and those who gives consent to participate in the study.
Exclusion Criteria
concomitant treatment for multiple types of primary cancer and decreased kidney function (glomerular filtration rate <60 mL/min/1.73 m2) since this significantly impacts the concentration of HE4.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To find out cut off values for CA125 & He4 in relation to optimal cytoreduction for advanced epithelial ovarian malignancy in both primary and interval debulking surgery in our settings.Timepoint: baseline
- Secondary Outcome Measures
Name Time Method /ATimepoint: N/A